文献速递心脏核医学放射性药物与辐射防护

炎症成像的过去、现在与未来:聚焦心血管免疫学

Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology.
PubMed 文献 · J Nucl Med · 2023-01-01

综述指出免疫系统是心血管疾病进展的关键介质和治疗靶点,炎症细胞活性贯穿从早期动脉粥样硬化到心肌梗死、心肌病和慢性心力衰竭的全谱系疾病。临床炎症成像长期依赖18F-FDG这一非选择性粗略标志物,而靶向不同白细胞亚群表面标志物的新型探针有望可视化并定量心脏和血管壁炎症的不同阶段,推动影像引导的机制性精准医学。

要点

  • 免疫系统参与从早期动脉粥样硬化到慢性心力衰竭的全谱系心血管疾病。
  • 18F-FDG是非选择性且粗略的炎症细胞活性标志物,新探针靶向不同白细胞亚群表面标志物。
  • 分子影像与免疫心血管病学并行发展,有望通过影像引导优化治疗并走向诊疗一体化。

核心结论

  • 免疫心血管病学与分子影像的并行发展提供了利用影像引导优化治疗、构建机制性精准医学的机会。

研究设计与样本

  • 综述类文章,讨论免疫细胞分子影像在心脏病学中从过去使用18F-FDG到目前放射性示踪剂库扩展、再到未来共享靶点的示踪剂-治疗化合物对诊疗一体化范式的进展。

主要发现

  • 从早期动脉粥样硬化到心肌梗死、心肌病和慢性心力衰竭的全谱系疾病均可见炎症细胞活性增加。
  • 调节炎症的治疗策略在临床前动物模型中显示希望,但在患者中疗效有限,部分原因是炎症严重程度存在个体差异。
  • 参与心脏病不同方面的白细胞亚群多样,使有效治疗面临挑战,需要适当平衡炎症的有害和有益方面。
  • 无创分子影像能够在组织水平探查心脏和血管中的炎症细胞,提供疾病进展的机制和时间信息。
  • 临床影像一直依赖18F-FDG作为炎症细胞活性的非选择性且粗略的标志物。

关键数值与推荐

  • 靶向不同白细胞亚群细胞表面标志物的新成像探针提供了可视化和定量心脏及血管壁炎症不同阶段的机会。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Growing evidence implicates the immune system as a critical mediator of cardiovascular disease progression and a viable therapeutic target. Increased inflammatory cell activity is seen in the full spectrum of disorders from early-stage atherosclerosis through myocardial infarction, cardiomyopathy, and chronic heart failure. Although therapeutic strategies to modulate inflammation have shown promise in preclinical animal models, efficacy in patients has been modest owing in part to the variable severity of inflammation across individuals. The diverse leukocyte subpopulations involved in different aspects of heart disease pose a challenge to effective therapy, wherein adverse and beneficial aspects of inflammation require appropriate balance. Noninvasive molecular imaging enables tissue-level interrogation of inflammatory cells in the heart and vasculature to provide mechanistic and temporal insights into disease progression. Although clinical imaging has relied on 18F-FDG as a nonselective and crude marker of inflammatory cell activity, new imaging probes targeting cell surface markers of different leukocyte subpopulations present the opportunity to visualize and quantify distinct phases of cardiac and vessel wall inflammation. Similarly, therapies are evolving to more effectively isolate adverse from beneficial cell populations. This parallel development of immunocardiology and molecular imaging provides the opportunity to refine treatments using imaging guidance, building toward mechanism-based precision medicine. Here, we discuss progress in molecular imaging of immune cells in cardiology from use of 18F-FDG in the past to the present expansion of the radiotracer arsenal and then to a future theranostic paradigm of tracer-therapy compound pairs with shared targets. We then highlight the critical experiments required to advance the field from preclinical concept to clinical reality.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Thackeray JT, Lavine KJ, Liu Y, et al. Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology. J Nucl Med. 2023. PMID: 37918845. doi:10.2967/jnumed.122.264865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。